Valuation: Edesa Biotech, Inc.

Market Cap 5.42Cr 4.81Cr 4.5Cr 4.1Cr 7.72Cr 521.66Cr 7.83Cr 54Cr 21Cr 265.67Cr 20Cr 20Cr 853.32Cr P/E 2026 *
-2.02x
P/E 2027 * -1.94x
Enterprise Value 5.42Cr 4.81Cr 4.5Cr 4.1Cr 7.72Cr 521.66Cr 7.83Cr 54Cr 21Cr 265.67Cr 20Cr 20Cr 853.32Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.5%
Yield 2026 *
-
Yield 2027 * -
1 day-4.75%
1 week-0.50%
Current month-4.75%
1 month-16.11%
3 months-48.26%
6 months-27.75%
Current year+182.39%
1 week 3.47
Extreme 3.47
4.27
1 month 3.47
Extreme 3.47
5.1
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
62.65
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 01/08/2015
Director of Finance/CFO 57 01/05/2025
President 48 07/06/2019
Director TitleAgeSince
Chairman 50 07/06/2019
Director/Board Member 55 07/06/2019
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Free

Founder

5,714 0.0593%
03/08/26 Free

Founder

5,324 0.0553%
02/07/26 Free

Founder

3,378 0.0380%
Change 5-day change 1-year change 3-year change Capi.($)
-4.75%-0.50%+56.03%-9.36% 5.69Cr
+4.16%+3.04%+49.37%+94.17% 7.45TCr
-0.61%+0.81%+27.25%+82.72% 6.01TCr
-2.54%-1.65%+4.86%+31.72% 4.82TCr
-3.02%-5.20%+27.94%+32.51% 4.43TCr
+0.31%+3.02%+348.95%+643.82% 4.4TCr
-1.96%-0.33%+7.04%+99.46% 4.16TCr
+3.32%+3.49%+10.10%+51.23% 3TCr
-3.39%+2.26%+28.80%+21.93% 2.93TCr
-4.86%-10.66%-26.27%+330.06% 2.49TCr
Average -1.32%-0.12%+53.41%+137.83% 3.97TCr
Weighted average by Cap. -0.43%+0.11%+57.77%+145.69%

Financials

2026 *2027 *
Net sales - -
Net income -1.75Cr -1.56Cr -1.46Cr -1.33Cr -2.5Cr -168.73Cr -2.53Cr -18Cr -6.82Cr -86Cr -6.58Cr -6.44Cr -276Cr -2.39Cr -2.12Cr -1.98Cr -1.81Cr -3.4Cr -229.9Cr -3.45Cr -24Cr -9.29Cr -117.08Cr -8.96Cr -8.77Cr -376.06Cr
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
-
Date Price Change Volume
01/26/01 $4.010 -4.75% 15,477
30/26/30 $4.210 +18.26% 84,916
29/26/29 $3.560 -2.47% 41,248
28/26/28 $3.650 -8.98% 48,339
25/26/25 $4.010 -0.50% 16,764
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.010USD
Average target price
16.33USD
Spread / Average Target
+307.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock